Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of ADI PEG 20 Plus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

NCT02101593 is registered in ClinicalTrials.gov with Polaris Group as lead sponsor.

NCT NCT02101593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02101593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of ADI PEG 20 Plus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Lead sponsor
Polaris Group
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2014
Completion date
March 31, 2016
Enrollment
8 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma